Development-stage biopharmaceutical company NLS Pharmaceutics Ltd. and Kadimastem Ltd., a clinical stage cell therapy company, announced on Friday shareholder approval of their merger at a special general meeting.
This approval marks a significant step toward forming a Nasdaq-traded biotechnology company with a strong portfolio targeting neurodegenerative diseases and diabetes. NLS plans to hold a shareholder meeting for final approval of the merger.
The collaboration reflects a shared commitment to advancing innovative therapies for unmet medical needs. Both companies are aligning efforts to enhance their impact in the biopharmaceutical sector. Progress on the merger reinforces their strategic vision for growth and innovation.
Insilico Medicine names new vice president, Clinical Development – Oncology
Kelun-Biotech reports fourth indication for sac-TMT approved by NMPA in HR+/HER2- breast cancer
Delonix Bioworks gets IND clearance for DX-104 in China
Innovent Biologics collaborates with Eli Lilly to develop new oncology and immunology treatments
K36 Therapeutics completes first patient cohort dosing for Phase 1 trial of KTX-2001
Cumberland Pharmaceuticals secures FDA Fast Track status for DMD heart‑disease therapy ifetroban
Hologic receives FDA approval for Aptima HPV assay as primary screening option
Cizzle Biotechnology secures Canadian patent for lung cancer biomarker test
Biosion reports first patient dosed in Phase 1a/1b trial of BSI-082
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer